Results 31 to 40 of about 65,267 (260)

Carcinogenesis of Pancreatic Ductal Adenocarcinoma [PDF]

Gastroenterology, 2020
Although the estimated time for development of pancreatic ductal adenocarcinoma (PDA) is more than 20 years, PDAs are usually detected at late, metastatic stages. PDAs develop from duct-like cells through a multistep carcinogenesis process, from low-grade dysplastic lesions to carcinoma in situ and eventually to metastatic disease.
Peter, Storz, Howard C, Crawford
openaire   +2 more sources

Features of immunophenotype of pancreatic ductal adenocarcinoma

Zaporožskij Medicinskij Žurnal, 2014
Aim. To determine features of immunophenotype of pancreatic ductal adenocarcinoma. Methods and results. At the immunohistochemical research of biopsy and postoperative material of 120 patients with pancreatic ductal adenocarcinoma the expression ...
A. V. Evseyev
doaj   +1 more source

Solitary metastasis to the head of the pancreas from lung adenocarcinoma mimicking pancreatic ductal adenocarcinoma: A case report

Radiology Case Reports
Solitary pancreatic metastasis is a rare cause of pancreatic neoplasm. Pancreatic ductal adenocarcinoma is the primary differential consideration when a solitary pancreatic mass is diagnosed, as it is the most common solitary solid pancreatic neoplasm. A
Mostafa Amor, M. Azfar Siddiqui, Irfan Amir Kazi, Asad Kabir, Ayesha Nasrullah   +4 more
doaj   +1 more source

The anti-tumor effect of HDAC inhibition in a human pancreas cancer model is significantly improved by the simultaneous inhibition of cyclooxygenase 2. [PDF]

PLoS ONE, 2013
Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer death worldwide, with no satisfactory treatment to date. In this study, we tested whether the combined inhibition of cyclooxygenase-2 (COX-2) and class I histone deacetylase (HDAC ...
Olivier Peulen, Arnaud Gonzalez, Paul Peixoto, Andrei Turtoi, Denis Mottet, Philippe Delvenne, Vincent Castronovo   +6 more
doaj   +1 more source

Mass-Forming Chronic Pancreatitis: Diagnostic Performance of PET/CT

World Journal of Nuclear Medicine, 2022
Mass-forming chronic pancreatitis and pancreatic ductal adenocarcinoma are most commonly located in the head of pancreas, and there is a marked overlap in clinical features and imaging findings that makes it diagnostically challenging, although prognosis
Ravikanth Reddy
doaj   +1 more source

Advanced Pancreatic Ductal Adenocarcinoma: Moving Forward [PDF]

Cancers, 2020
Globally, the death rate of pancreatic ductal adenocarcinoma (PDAC) has doubled over 30 years and is likely to further increase, making PDAC a leading cause of cancer-related death in the coming years. PDAC is typically diagnosed at an advanced stage, and modified FOLFIRINOX or nab-paclitaxel and gemcitabine are the mainstay of systemic therapy.
Caspar Franck, Christian Müller, Rosa Rosania, Roland S. Croner, Maciej Pech, Marino Venerito   +5 more
openaire   +4 more sources

The induction of peripheral trained immunity in the pancreas incites anti-tumor activity to control pancreatic cancer progression

Nature Communications, 2022
The advent of immunotherapy has revolutionised cancer therapeutics, but its application in the context of pancreatic ductal adenocarcinoma has been limited.
Anne E. Geller, Rejeena Shrestha, Matthew R. Woeste, Haixun Guo, Xiaoling Hu, Chuanlin Ding, Kalina Andreeva, Julia H. Chariker, Mingqian Zhou, David Tieri, Corey T. Watson, Robert A. Mitchell, Huang-ge Zhang, Yan Li, Robert C. G. Martin II, Eric C. Rouchka, Jun Yan   +16 more
doaj   +1 more source

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source

Identification of serum protein biomarkers for pre‐cancerous lesions associated with pancreatic ductal adenocarcinoma

Molecular Oncology, EarlyView.
This work identified serum proteins associated with pancreatic epithelial neoplasms (PanINs) and early‐stage PDAC. Proteomics screens assessed genetically engineered mice with abundant PanINs, KPC mice (Lox‐STOP‐Lox‐KrasG12D/+ Lox‐STOP‐Lox‐Trp53R172H/+ Pdx1‐Cre) before PDAC development and also early‐stage PDAC patients (n = 31), compared to benign ...
Hannah Mearns, Jaclyn S. Long, Sergio Lilla, Kelly Hodge, Marcus J. G. W. Ladds, Colin Nixon, Paula Fernández‐Palanca, Sara Zanivan, Pilar Acedo, Stephen P. Pereira, Kevin M. Ryan   +10 more
wiley   +1 more source